Figure 4
Figure 4. In vivo activity of the major and minor forms of wild-type mature VEGF-D. Tibialis anterior muscles of Balb/c mice were injected with rAAVs encoding the indicated cDNAs (D89-195, the N-terminal major form of the mature human VEGF-D, residues 89-195; D100-195, the N-terminal minor form of the mature human VEGF-D, residues 100-195; and HSA, human serum albumin, as a control) and analyzed 2 weeks later by immunohistochemistry of frozen sections. (A) Schematic representation of the rAAV vectors. (B) Representative images of the staining. (C) Quantification of stained area from ≥ 5 randomly chosen view fields (D89, D89-195;D100, D100-195). PECAM-1, SMA, and the lymphangiogenic antibodies lymphatic endothelial hyaluronan receptor-1 (LYVE-1), Prox-1, and podoplanin were used for immunostaining. *P < .05, **P < .01.

In vivo activity of the major and minor forms of wild-type mature VEGF-D. Tibialis anterior muscles of Balb/c mice were injected with rAAVs encoding the indicated cDNAs (D89-195, the N-terminal major form of the mature human VEGF-D, residues 89-195; D100-195, the N-terminal minor form of the mature human VEGF-D, residues 100-195; and HSA, human serum albumin, as a control) and analyzed 2 weeks later by immunohistochemistry of frozen sections. (A) Schematic representation of the rAAV vectors. (B) Representative images of the staining. (C) Quantification of stained area from ≥ 5 randomly chosen view fields (D89, D89-195;D100, D100-195). PECAM-1, SMA, and the lymphangiogenic antibodies lymphatic endothelial hyaluronan receptor-1 (LYVE-1), Prox-1, and podoplanin were used for immunostaining. *P < .05, **P < .01.

Close Modal

or Create an Account

Close Modal
Close Modal